Cladribine in the Treatment of Langerhans Cell Histiocytosis: A Summary of the Literature

Langerhans cell Histiocytosis (LCH) is a rare disease for which treatment with 2- chlorodeoxyadenosine (cladribine) has changed disease outcome. Cladribine has meanwhile been administered over two decades and is available for intravenous and subcutaneous administration. Cladribine has been administered in treatment of therapy naïve, relapsed and refractory LCH and induces high response rates, regardless of prior treatment. Literature describing the use of cladribine either alone or in combination with cytarabine is summarized herein.


Marlies E.H.M. van Hoef

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
30+ Million Readerbase
Recommended Conferences
Google scholar citation report
Citations : 158

Journal of Rare Disorders: Diagnosis & Therapy received 158 citations as per google scholar report

Journal of Rare Disorders: Diagnosis & Therapy peer review process verified at publons
Abstracted/Indexed in
  • Google Scholar
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • Publons
  • Secret Search Engine Labs
  • Euro Pub

View More »

Flyer image


agar io


wormax io